{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:04:38Z","timestamp":1781514278868,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["19P02809 \/ 19E00844"],"award-info":[{"award-number":["19P02809 \/ 19E00844"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["19P02809 \/ 19E00844"],"award-info":[{"award-number":["19P02809 \/ 19E00844"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["19P02809 \/ 19E00844"],"award-info":[{"award-number":["19P02809 \/ 19E00844"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["19P02809 \/ 19E00844"],"award-info":[{"award-number":["19P02809 \/ 19E00844"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["19P02809 \/ 19E00844"],"award-info":[{"award-number":["19P02809 \/ 19E00844"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["19P02809 \/ 19E00844"],"award-info":[{"award-number":["19P02809 \/ 19E00844"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Radiotherapy as a complement or an alternative to neurosurgery has a central role in the treatment of skull base grade I-II meningiomas. Radiotherapy techniques have improved considerably over the last two decades, becoming more effective and sparing more and more the healthy tissue surrounding the tumour. Currently, hypo-fractionated stereotactic radiotherapy (SRT) for small tumours and normo-fractionated intensity-modulated radiotherapy (IMRT) or proton-therapy (PT) for larger tumours are the most widely used techniques. It is expected a decrease of the risk of cognitive impairment with these modern techniques. However prospective data about cognitive long-term consequences of partial brain irradiation with SRT, PT, or IMRT remain very scarce to date.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>CANCER COG is one of the first multicentric study in the world to prospectively assess the cognitive performances of patients following different modalities of cerebral radiotherapy (stereotactic radiotherapy, proton therapy, intensity modulated radiotherapy) for the treatment of grade I-II skull base meningioma, up to at least 10 years after the end of radiotherapy. This longitudinal study includes the follow-up of 3 cohorts, including: patients treated with PRT, IMRT, and SRT. An additionally control group will be formed. The primary objective is to report long-term cognitive deterioration in each cohort until 10 years after the end of irradiation. The rate of clinical symptomatology improvement over time after irradiation, the evolution of health-related quality-of-life, anxiety\/depression, fatigue, over time after irradiation, the tumoral local control after irradiation, the progression-free survival (PFS), the professional reintegration for working-age patients will also be assessed. CANCER COG aims to help clinicians to choose the best irradiation techniques with the best benefit\/risk ratio. Inclusions started on september 2023.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>The study was registered on clinicaltrials.gov with the following number: NCT 06036706.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13014-025-02591-1","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T15:32:29Z","timestamp":1738164749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neurocognitive impact of different irradiation modalities for patients with grade I-II skull base meningioma: a prospective multi-arm cohort study (CANCER COG)"],"prefix":"10.1186","volume":"20","author":[{"given":"Paul","family":"Lesueur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Clarisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Lequesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinu","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Balosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Thureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Capel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Castera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Goliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Michel","family":"Grellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Tessonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Castel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Valable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"2591_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nrneurol.2016.185","volume":"13","author":"MT Makale","year":"2017","unstructured":"Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S. Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours. Nat Rev Neurol. 2017;13:52\u201364.","journal-title":"Nat Rev Neurol"},{"key":"2591_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1474-4422(04)00680-5","volume":"3","author":"MJB Taphoorn","year":"2004","unstructured":"Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3:159\u201368.","journal-title":"Lancet Neurol"},{"key":"2591_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1748-717X-7-77","volume":"7","author":"AV Tallet","year":"2012","unstructured":"Tallet AV, Azria D, Barlesi F, Spano J-P, Carpentier AF, Gon\u00e7alves A, et al. Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol. 2012;7:77.","journal-title":"Radiat Oncol"},{"key":"2591_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s11910-010-0108-4","volume":"10","author":"DD Correa","year":"2010","unstructured":"Correa DD. Neurocognitive function in brain tumors. Curr Neurol Neurosci Rep. 2010;10:232\u20139.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2591_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11060-012-0821-8","volume":"108","author":"S Scoccianti","year":"2012","unstructured":"Scoccianti S, Detti B, Cipressi S, Iannalfi A, Franzese C, Biti G. Changes in neurocognitive functioning and quality of life in adult patients with brain tumors treated with radiotherapy. J Neurooncol. 2012;108:291\u2013308.","journal-title":"J Neurooncol"},{"key":"2591_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nrneurol.2012.182","volume":"8","author":"L Padovani","year":"2012","unstructured":"Padovani L, Andr\u00e9 N, Constine LS, Muracciole X. Neurocognitive function after radiotherapy for paediatric brain tumours. Nat Rev Neurol. 2012;8:578\u201388.","journal-title":"Nat Rev Neurol"},{"key":"2591_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ijrobp.2012.11.031","volume":"85","author":"V Gondi","year":"2013","unstructured":"Gondi V, Hermann BP, Mehta MP, Tom\u00e9 WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2013;85:348\u201354.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2591_CR8","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1136\/jnnp.2007.138925","volume":"80","author":"M Dijkstra","year":"2009","unstructured":"Dijkstra M, van Nieuwenhuizen D, Stalpers LJA, Wumkes M, Waagemans M, Vandertop WP, et al. Late neurocognitive sequelae in patients with WHO grade I meningioma. J Neurol Neurosurg Psychiatry. 2009;80:910\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2591_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1053\/j.semnuclmed.2006.10.002","volume":"37","author":"PC Tumeh","year":"2007","unstructured":"Tumeh PC, Alavi A, Houseni M, Greenfield A, Chryssikos T, Newberg A, et al. Structural and functional imaging correlates for age-related changes in the brain. Semin Nucl Med. 2007;37:69\u201387.","journal-title":"Semin Nucl Med"},{"key":"2591_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00234-013-1297-8","volume":"56","author":"W Bian","year":"2014","unstructured":"Bian W, Hess CP, Chang SM, Nelson SJ, Lupo JM. Susceptibility-weighted MR imaging of radiation therapy-induced cerebral microbleeds in patients with glioma: a comparison between 3T and 7T. Neuroradiology. 2014;56:91\u20136.","journal-title":"Neuroradiology"},{"key":"2591_CR11","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/j.ijrobp.2011.05.046","volume":"82","author":"JM Lupo","year":"2012","unstructured":"Lupo JM, Chuang CF, Chang SM, Barani IJ, Jimenez B, Hess CP, et al. 7-Tesla susceptibility-weighted imaging to assess the effects of radiotherapy on normal-appearing brain in patients with glioma. Int J Radiat Oncol Biol Phys. 2012;82:e493\u2013500.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2591_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/neuonc\/noy137","volume":"21","author":"RY Huang","year":"2019","unstructured":"Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, et al. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2019;21:26\u201336.","journal-title":"Neuro Oncol"}],"updated-by":[{"DOI":"10.1186\/s13014-025-02650-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000}}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02591-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02591-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02591-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T20:33:53Z","timestamp":1745958833000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02591-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2591"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02591-1","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13014-025-02650-7","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13014-025-02650-7","URL":"https:\/\/doi.org\/10.1186\/s13014-025-02650-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has received ethical approval from the Comit\u00e9 de protection des personnes Ouest VI. All patients will give their written informed consent before any study relative assessment start.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}